


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/316,226
Filing Date	May 21, 1999
First Named Inventor	M. Rigdon Lentz
Group Art Unit	3762
Examiner Name	
Attorney Docket Number	LEN 101 CIP

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
m		4,708,713		Lentz	11-24-1987	
		5,135,919		Folkman, et al	08-04-1992	
		5,147,638		Esmon, et al	09-15-1992	
		5,290,807		Folkman, et al.	03-01-1994	
		5,629,327		D'Amato	05-13-1997	
		5,639,725		O'Reilly, et al.	06-17-1997	
		5,698,586		Kishimoto, et al.	12-16-1997	
		5,712,291		D'Amato	01-27-1998	
		5,713,491		Hughes, et al.	02-03-1998	
		5,716,981		Hunter, et al	02-10-1998	
		5,733,876		O'Reilly, et al.	03-31-1998	

RECEIVED
SEP - 3 1999
TO STUDY MAIL ROOM

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
m		CHEN, et al., "Soluble TNF- Receptors are constitutively shed and downregulate adhesion molecule expression in malignant gliomas," <i>J. Neuropathol. Exp. Neurol.</i> 56(5):541-550 (1997).	
1		COLMAN, et al., <u>Hemostasis and Thrombosis: Basic Principles and Clinical Practice</u> (2nd Ed.), p. 263, J.B.Lippincott:Philadelphia, PA, 1987.	
		JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," <i>Arch Immunol Ther Exp (Warsz)</i> . 45(5-6):449-53 (1997).	
m		MATSCHINER, et al., <u>Current Advances in Vitamin K Research</u> , pp. 135-140, (John W. Suttie, ed.) Elsevier Science Publishing Co., Inc., 1988.	

Examiner's Signature	<i>William M. [Signature]</i>	Date Considered	1/14/00
----------------------	-------------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.